5-hydroxytryptamine-3 receptors are involved in the initiation of gastric phase-3 motor activity in humans.
BACKGROUND
5-hydroxytryptamine-3 (5-HT3) receptor antagonists inhibit gastric phase-3 motor activity in the dog. This study examined the role of 5-HT3 receptors in the generation of gastric phase 3 of the migrating motor complex in humans.


METHODS
Interdigestive motor activity was recorded manometrically in 16 subjects before and after administration of ondansetron, a selective 5-HT3 receptor antagonist. Plasma motilin values were also assayed in 7 individuals. The incidence of gastric activity fronts before and after ondansetron was compared with a control group that had not received ondansetron. The ability of erythromycin to induce a gastric activity front in the presence of ondansetron was also evaluated in 7 subjects.


RESULTS
The incidence of gastric activity fronts was 69% before ondansetron vs. 19% after ondansetron. In contrast, in the control group there was no significant change in the incidence of gastric activity fronts over time. Activity fronts preceding ondansetron were associated with motilin peaks while activity fronts after ondansetron were not. Despite the previous administration of ondansetron, erythromycin induced gastric activity fronts in 89% of cases.


CONCLUSIONS
Selective antagonism of 5-HT3 receptors suppresses the gastric component of phase-3 motor activity and simultaneously suppresses plasma motilin peaks. The results suggest that the suppression of gastric activity fronts is achieved via the suppression of plasma motilin peaks because in the presence of ondansetron a motilin agonist like erythromycin restores the gastric phase 3.
Wilmer
A
A
Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium.
Tack
J
J
Coremans
G
G
Janssens
J
J
Peeters
T
T
Vantrappen
G
G
D000328:Adult; D004064:Digestive System / Q000294:innervation; D004068:Digestive System Physiological Phenomena; D004386:Duodenum / Q000294:innervation / Q000502:physiology; D004917:Erythromycin / Q000494:pharmacology; D005260:Female; D006801:Humans; D007583:Jejunum / Q000294:innervation / Q000502:physiology; D008297:Male; D009037:Motilin / Q000097:blood; D009043:Motor Activity / Q000502:physiology*; D009046:Motor Neurons / Q000502:physiology; D017294:Ondansetron / Q000494:pharmacology; D011706:Pyloric Antrum / Q000294:innervation / Q000502:physiology; D011985:Receptors, Serotonin / Q000502:physiology*; D013270:Stomach / Q000294:innervation / Q000502:physiology*
D011985:Receptors, Serotonin; D017294:Ondansetron; D009037:Motilin; D004917:Erythromycin